Infinity Pharmaceuticals, Inc. (INFI - Free Report) reported a loss of 14 cents per share in fourth-quarter 2017, narrower than the Zacks Consensus Estimate of a loss of 27 cents. The company had reported a loss of 46 cents in the year-ago quarter.
Since Infinity does not have any approved product in its portfolio, the company earns revenues in the form of royalties, license and milestone payments as well as research and development (R&D) support fees paid by its partners.
Infinity’s shares have declined 15.7% over a year against the industry’s gain of 3.8%.
Quarter in Detail
In the quarter, R&D expenses plummeted to $3.6 million from $14.7 million in the year-ago quarter. The decline was mainly due to the company's 2016 restructuring activities and out-licensing of duvelisib to Verastem Inc. (VSTM - Free Report) .
General and administrative (G&A) expenses were $4.5 million for the quarter, down from $8.6 million in the year-ago quarter. The decrease was mainly due to the company's 2016 restructuring activities.
Infinity expects net loss for 2018 to be in the range of $35-$40 million. The company anticipates year-end cash and cash equivalents and available-for-sale securities balance in the $15-$25 million range. Moreover, Infinity expects that its existing cash, cash equivalents and available-for-sale securities as of Dec 31, 2017 should be adequate to fund the company's capital needs through third-quarter 2019.
The company reported a loss of 83 cents in 2017 compared with a loss of 61 cents in 2016.
Collaboration revenues in 2017 came in at $6 million, down from $18.7 million in 2016.
Infinity is evaluating IPI-549 as a monotherapy and in combination with Bristol-Myers’ (BMY - Free Report) Opdivo in a phase I study in patients with advanced solid tumors.
The phase I/Ib monotherapy and combination dose escalation components of the study have been completed and the monotherapy expansion component has been fully enrolled. Further, six disease-specific combination expansion cohorts are enrolling at the recommended phase II dose of 40 mg once daily of IPI-549 plus Opdivo at 240 mg every two weeks in patients with non-small cell lung cancer, melanoma, head and neck cancer, triple-negative breast cancer, mesothelioma, and adrenocortical carcinoma.
An additional combination expansion cohort of patients pre-selected for having high baseline blood levels of myeloid derived suppressor cells is expected to open for enrollment in the next few weeks.
In November 2017, Infinity announced updated data from the monotherapy dose-escalation component of the Phase I/Ib study of IPI-549 at the SITC Annual Meeting 2017. These data demonstrated that IPI-549 dosed once daily was well tolerated and clinically active.
The company believes that IPI-549 has the potential to increase the number of patients who respond to immunotherapies as well as to increase the duration of those responses.
The company expects to report data from the monotherapy expansion and combination dose escalation components of its study and from seven combination expansion cohorts which will help define the development and regulatory strategy for IPI-549.
The restructuring initiatives taken by the company have lowered operating expenses. We expect the initiatives to have a significant positive cumulative effect on the company’s margin.
Zacks Rank & Key Pick
Infinity has a Zacks Rank #3 (Hold).
A better-ranked stocks from the same space is Regeneron Pharmaceuticals (REGN - Free Report) sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates have moved up from $18.65 to $18.68 for 2018 in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, the average beat being 9.15%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>